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Abstract
We investigate the role of resting tension on thrombin (THR) induced relaxation of guinea-pig tracheas precontracted with acetylcholine
(ACh).
Isometric contractions of isolated guinea-pig tracheas were recorded at 4 and 6 g resting tension; and ACh dose–response curves were
performed.
THR relaxed ACh-precontracted tracheas and this effect was mimicked by the type 2 protease activating receptor agonist peptide (PAR-2
AP) and trypsin.
The relaxant effect of 3 U mlK1 THR and 100 nmol mlK1 PAR-2 AP was prevented at 4 g by preincubation with the nitric oxide synthase
(NOS) inhibitor L-NAME and at 6 g resting tension by ibuprofen and diclofenac. However, adenosine trisphospahate (ATP) relaxation was
totally prevented by cyclooxygenase (COX) inhibitors but not by NOS inhibitors at both resting tensions.
Resting tension influenced the effect of PGE2 on contractile tone of isolated guinea-pig tracheas, the maximal relaxation being K11.1G
2.97 and K2.0G0.46 mg mgK1 tissue wet weight at 6 and 4 g, respectively. Moreover, 30 nmol mlK1 PGE2 can relax ACh-precontracted
tracheas, being the effect up to 91 and 30% at 6 and 4 g, respectively.
These data demonstrate that trachea responsiveness is highly dependent on the smooth muscle length, revealing new aspects of stretch-
activated receptors that can influence trachea responsiveness in vivo.
q 2004 Elsevier Ltd. All rights reserved.
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In recent years, protease activated receptors (PARs) have
been described in several tissues, including the airways (for
a short review see [1]). In particular, the cytoprotective
activity of thrombin, trypsin and tethered-ligand peptides
SLIGRL-NH2 for PAR-2 and SFLLIRN-NH2 for PAR-1
has been originally described in mouse, rat, guinea-pig1094-5539/$ - see front matter q 2004 Elsevier Ltd. All rights reserved.
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E-mail address: paola.failli@unifi.it (P. Failli).and human isolated bronchi with epithelium [2]. In vitro,
both proteases can relax ACh-precontracted bronchi, this
relaxant effect being mainly mediated by the activation of
PAR-2 localised in the epithelium. In the absence of
epithelium, both peptides are ineffective. Moreover, in vivo
aerosol administration of SLIGRL-NH2 inhibits serotonin-
induced bronchoconstriction in rats [2]. The relaxing effect
in vitro of proteases is prevented by the cyclooxygenase
inhibitors indomethacin and acetylsalicylic acid, suggesting
an involvement of cyclooxygenase metabolites in the PAR-
mediated relaxant effect. On the other hand, the block of NO
production does not influence the relaxing effect of both
peptides [2]. Subsequent research confirms the complex role
of proteases and their receptors in airway function,
demonstrating that PARs are localized not only inPulmonary Pharmacology & Therapeutics 18 (2005) 141–150www.elsevier.com/locate/ypupt
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lungs [1].
The isolated guinea-pig trachea also reacts to proteases.
According to the different in vitro preparations and
experimental conditions used, proteases can mediate either
relaxation [3] or contraction [4]. Moreover, the intravenous
administration of the PAR-2 activating peptide (PAR-2 AP)
SLIGRL (1 mg kgK1) can prevent in vivo histamine-induced
bronchoconstriction in guinea-pigs [5]. Also the involvement
of cyclooxygenase metabolites and NO in the relaxing effect
of PARs agonists has been further investigated in guinea-pigs
[3,5]. Whereas the inhibition of COX by indomethacin, and
the inhibition of nitric oxide synthetases (NOS) by u-N-
monomethyl-L-arginine (L-NMMA) can decrease the relax-
ant effect of PAR-2 activating peptide SLIGRL-NH2 in
guinea-pig tracheas in vitro [3], indomethacin and u-nitro-L-
arginine-methylester (L-NAME) in vivo are unable to
counteract the relaxant effect of PAR-2 AP [5]. According
to Carr et al. [4], trypsin can induce contractions in
indomethacin-pretreated tracheal preparations, this effect
being prevented by neurokinin receptor antagonists (type1
receptor, NK1). Therefore, several discrepancies on PARs
actions are still unexplained in literature.
In the mouse trachea, prostaglandin E2 (PGE2) is mainly
involved in this relaxant effect of PARs agonist, acting
through its E-prostanoid type 2 (EP2) receptor as demon-
strated with the DP/EP1/EP2 prostanoid receptor antagonist
AH6809 [6]. When comparing PGE2 effects on wild-type
and EP receptor-deficient mice, the tracheal relaxation due
to this lipid autacoid is dependent on EP2 receptors [7,8].
Moreover, ATP and substance P increase PGE2 release that
in turn stimulates EP2 receptors, thus mediating the relaxant
effect of PGE2 as determined with an EP2-deficient mice
model [7].
According to Asokananthan and co-authors [9], PAR-1,
PAR-2 and PAR-4 receptor agonists can stimulate the
release of PGE2 in human pulmonary epithelial cell lines
(A549 and HBECs). All peptides are similarly effective on
the A549 cell line, while the HBEC cell line produces a 10-
fold larger amount of PGE2 both at baseline and after
stimulation and is more responsive to the PAR-2 receptor
agonist.
Old data obtained in guinea-pig tracheal strips [10],
demonstrate that PGE2 as well as ATP are contractile
agonists at low resting tone, but relaxing agents when the
resting tension is set at high values and when the tension is
increased by histamine pre-treatment. Similar results are
also described by Advenier and co-authors [11] regarding
the effect of ATP and adenosine on guinea-pig tracheas.
Both molecules can relax ACh precontracted preparations,
but contract guinea-pig tracheas when the only tension
applied is resting tension. More recently, Watson et al. [12]
demonstrate that resting tension can influence the contrac-
tile response of isolated human bronchial ring preparations.
Although the contraction induced by 8 Hz electrical field
stimulation is monophasic independently of the appliedresting tension, when electrical field stimulation frequency
is increased up to 30 Hz, the contractile phase is followed by
a relaxation when preparations are stretched at high resting
tension. However, this biphasic behaviour is absent when
resting tension is set at lower values than the initial one. In
the same study, resting tension dependency is also
established by testing the effect of isoprenaline and
carbachol. Isoprenaline induces a significantly improved
relaxation when resting tension is set at low values [12].
Moreover, the contractile potency of carbachol (3 mM) is
only marginally decreased when the resting tension is high.
On the other hand, at high resting tension and when
preparations after carbachol challenge are extensively
washed (60 min), bronchial tissue specimens recover to
significantly lower tension values than those measured
before muscarinic stimulation.
According to preliminary data obtained in our laboratory,
the applied isometric stretching (i.e. resting tension) can
modify smooth muscle responsiveness to several agonists.
Stretch (resting tension) is an essential determinant of
muscular fibre length and it can mimic experimentally the
change in smooth muscle length related to the physiological
breathing process, when the airways are submitted to cyclic
changes in volume.
Therefore, we decided to investigate the possible
influence of resting tension on PARs responsiveness in
isolated guinea-pig trachea since no effort have been made
to relate the PARs reactivity to this experimental parameter.
In order to better clarify this point, ATP was mainly used to
compare PARs response to a more traditional relaxing
agent, but since several experiments had revealed peculiar
aspects of ATP pharmacology, numerous data on ATP were
also described below.2. Methods
This investigation conforms to European Union rules for
the care and use of laboratory animals.
Pathogen-free white male guinea-pigs (300–350 g)
were obtained from Harlan (Italy), housed under con-
trolled conditions and used at least two weeks after their
arrival in our animal facilities. Commercial chow and
water were allowed ad libitum. Animals were anaesthe-
tised with sodium thiopental (80 mg kgK1 i.p.) and killed
by cervical dislocation. Tracheas were dissected free of
connective tissue and placed in cold gassed (5% CO2 in
O2) Krebs–Henseleit solution (K–H) of the following
composition (mM): 110 NaCl, 25 NaHCO3, 4.8 KCl, 1.2
KH2PO4, 1.2 MgSO4, 11 mM D(C)glucose, 2.5 mM
CaCl2 and cut into helical strips (3 mm width, 20 mm
length). Strips were mounted in an organ bath (2 ml) with
one end attached to a tissue holder and the other to a
research grade isometric force transducer (Harvard
Apparatus, Inc., South Natick, Massachusetts, USA)
connected to an analogical/digital converter. Signal was
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Italy); the real-time tissue response data were continu-
ously collected, displayed on the computer screen and
recorded as ASCII data files. Strips were perfused with
pre-warmed (37 8C) K–H, gassed with 5% CO2 in O2.The
resting tension was set at 4 or 6 g and the tissue was
equilibrated for at least 60 min before starting with
experimental protocols. These resting tensions were
arbitrarily chosen in the range in which ACh induced an
appreciable contraction and its dose–response curve was
superimposable. After equilibration, tension was assumed
as 0 mg mgK1 tissue wet weight (w.w.). Cumulative dose–
response curves were performed by adding as a bolus
incremental doses of ACh to the closed 2 ml organ bath.
The maximal contraction obtained was expressed as 100%
of contractile response and the cumulative dose–response
curve of ATP and thrombin (THR) was made using the
maximal ACh dose (100%). The functionality of each
preparation was tested in control conditions by assessing
the relaxant effect of ATP in ACh-precontracted trachea
strips. However, using ATP we obtained distinguishing
data, that therefore were reported in the result section.
Experiments were mostly performed on epithelium-intact
preparations; in several experiments the epithelial layer
was rubbed with a cotton gauze and tracheas were then
mounted as above indicated. ACh, THR, trypsin, ATP,
and PARs peptides were administered as a bolus injection
to the closed 2 ml organ bath. Since the effect of proteases
implies a proteolytic degradation of their receptors,
experiments aimed to test the effect of proteases in
different experimental conditions were run in parallel on
two different tracheal preparations. According to the
experimental protocol, after assessing functionality in
control conditions, tracheas were perfused (5 ml minK1)
with K–H containing L-NAME, 2-phenyl-4,4,5-tetra-
methyl-imidazoline-1-oxyl-3-oxide (PTIO, a NO trapping
agent, [13]), ibuprofen or diclofenac at specified concen-
trations for at least 30 min (open organ bath) before the
ACh bolus administration and maintained throughout the
remaining experimental time. Cumulative dose–response
curves were also performed by adding incremental doses
of PGE2 as a bolus to the closed 2 ml organ bath. In
several experiments, PAR-2 was administered to the ACh-
precontracted trachea and ATP, THR or trypsin were
administered to the already relaxed specimen.
2.1. PGE2 quantification
PGE2 tissue release in the organ bath was quantified
using radioimmune [125I] assay (RIA) kits (Amhersham
Biosciences UK Limited, Buckinghamshire England).
Briefly, at the end of stabilisation time, the organ bath was
closed and its content was carefully collected after 6 min
and immediately frozen at K80 8C. The organ bath was then
rapidly replenished, 10 nmol mlK1 ACh administered and
after 3 min a bolus dose of the buffer alone was addedand, after an additional 3 min period, the organ bath
medium was collected and stored at K80 8C. The organ
bath was refilled and 3 min after ACh administration
(10 nmol mlK1), strips received either 100 nmol mlK1
ATP or 3 U mlK1 THR, and the organ bath buffer collected
after 3 min. Then, the above-described procedure was
repeated, switching from ATP to THR and vice versa.
Preparations received first ATP or THR alternatively.
Preparations were then incubated for 60 min with 1 mM
diclofenac (perfusion) and the entire protocol was repeated,
maintaining diclofenac throughout the experiment. The
collecting time of 3 minC3 min was selected as necessary
and sufficient to obtain the ACh maximal contractile value
as well as to obtain the complete relaxation after ATP or
THR. Experiments were performed on different tracheas at
4 and 6 g resting tension. The functional real-time response
of each preparation was continuously monitored. Collected
media were immediately lyophilised and processed for
PGE2 dosage as described by the manufacturer. The PGE2
standard was also lyophilised in K–H solution and run
similarly. The assay was performed in duplicate. Method
sensibility was 8 pg mlK1.
2.2. Nitric oxide quantification
NO tissue release in the organ bath was quantified using a
chemiluminescence NO analyser (model 280 NOA; Sievers;
Boulder, CO, USA). The protocol used to collect organ bath
medium was very similar to that for quantifying PGE2
release. However, after collecting organ bath media in
control conditions, strips were incubated for 30 min with
100 mM L-NAME. Media immediately frozen at K80 8C in
sterile test tubes were directly used for NO dosage. The
calibration curve was performed by dissolving NaNO2
directly in K–H buffer and processing the standards
similarly to the unknown samples. Method sensibility was
1 nmol lK1.
2.3. Materials
Trypsin, acetylcholine (ACh), ibuprofen sodium salt,
diclofenac sodium salt, and 2-phenyl-4,4,5-tetramethyl-
imidazoline-1-oxyl-3-oxide (PTIO) were obtained from
Sigma Chemical Co. (St Louis, MO, USA); thrombin
(from bovine blood) from Roche Molecular Biochemicals
(Switzerland) and units, as referred in the text, were
measured using the chromogenic substrate Chromozymw
TH; u-nitro-L-arginine methylester (L-NAME) from Cal-
biochem (La Jolla, CA, USA); S-nitroso-N-acetylpenicilla-
mine (SNAP) from Tocris Cookson Ltd (North Point, UK),
PGE2 from Cayman Chemical (Ann Arbor, MI, USA);
PAR-1 (SFLLIRN-NH2) from BACHEM (Bubendorf,
Switzerland); PAR-2 (SLIGKV-NH2), PAR-3 (TFRGAP-
NH2) and PAR-4 (GYPGKF-NH2) peptides from Inalco
(Milan, Italy). The concentration, amino acid composition
and purity were checked by the vendors.
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Values are presented as meansGs.e. mean. Dose–
response curves were analysed with linear regression and
compared with one-way ANOVA followed by Bonferroni’s
t test. Statistical comparisons between data groups were
performed using either one-way ANOVA followed by
Bonferroni’s t test or independently Student’s t test as
indicated. A P value %0.05 was considered significant.Fig. 2. Effect of adenosine triphosphate (ATP) on 10 nmol mlK1 ACh-
precontracted guinea-pig tracheal strips. The contraction obtained with
ACh was set as 100%. Cumulative dose–response curves of ATP were
performed at 4 and 6 g resting tension. ATP was administered as a bolus.
Values are the meanGs.e.m. of at least four experiments. For more details,
see Section 3.3. Results
3.1. Effect of ACh
Acetylcholine caused a dose-dependent contraction of
tracheal strips at both resting tensions studied (Fig. 1,
rZ0.970, P!0.01 and rZ0.976, P!0.001 at 4 and 6 g,
respectively); these dose–response curves were superimpo-
sable in the full range tested. Moreover, tracheas precon-
tracted with 10 nmol mlK1 ACh were still able to increase
tensions up to 10-fold (up to 30 mg mgK1 tissue wet weight)
when a depolarising dose of 100 mmol mlK1 KCl was
added. In order to investigate the effect of PAR agonists at
the different resting tensions we used the maximal
contractile bolus dose of 10 nmol mlK1 ACh.
3.2. Effect of ATP
ATP induced a dose-dependent relaxation of ACh-
precontracted tracheal strips (Fig. 2, rZK0.988, P!0.05
and rZK0.998, P!0.01 at 4 and 6 g, respectively).
These dose–response curves were superimposable, 100
nmol mlK1 ATP being able to induce up to 30% of
relaxation. However, in epithelium-rubbed preparations,
ATP was ineffective at both resting tensions. It should
be noted that in the absence of epithelium, 10 nmol mlK1
ACh induced a contraction of 4.6G0.27 mg mgK1 tissueFig. 1. Effect of acetylcholine (ACh) on isolated guinea-pig tracheal strips.
Cumulative dose–response curves of acetylcholine were performed at 4 and
6 g resting tension. ACh was administered as a bolus. Values are the
meanGs.e.m. of at least four experiments.(w.w., nZ3) and 5.0G0.19 mg mgK1 tissue (w.w., nZ3) at
4 and 6 g, respectively. These values were significantly
different from those obtained in the presence of epithelium
(P!0.05 and P!0.001 at 4 and 6 g, respectively, Student’s t
test for independent data).
Independently of resting tension, the relaxation induced
by 100 nmol mlK1 ATP was prevented when tracheal strips
were preincubated with COX-inhibitors (Fig. 3, panel A).
As shown, 10 mM ibuprofen and 1 mM diclofenac were
similarly effective in inhibiting the relaxation induced by
ATP. On the other hand, COX-inhibitors did not signifi-
cantly modify ACh-induced contraction (not shown).
Then we tested if endogenous NO contributes to the
relaxation induced by ATP. Strips were therefore pretreated
with the NOS inhibitor L-NAME (100 mM in perfusion for
30 min); however, as shown in Fig. 3 (panel B), the relaxant
effect of 100 nmol mlK1 ATP was unaffected. 1 mM PTIO
behaved similarly to L-NAME (not shown). Indeed, neither
100 mM L-NAME nor 1 mM PTIO were able to modify
either ACh-induced tracheal contraction or ATP-induced
relaxation.3.3. Effect of PARs agonists
THR can dose-dependently (0.3–10 U mlK1) relax ACh-
precontracted tracheal strips, with nearly 50% relaxation
being induced by a dose of 3 U mlK1. The superimposable
dose–dependent curves of thrombin are shown in Fig. 4
(rZK0.991, P!0.01 and rZK0.983, P!0.05 at 4 and
6 g, respectively). Similarly to ATP, THR was also
ineffective in relaxing epithelium-rubbed preparations at
both resting tensions. However, in 2 out of 4 preparations a
small contractile increase (6%) was observed when resting
tension was set at 4 g and in 3 out of 4 preparations stretched
at 6 g.
Fig. 3. Effect of COX inhibitors (panel A) and a NOS inhibitor (panel B) on ATP-induced relaxation of 10 nmol mlK1 ACh-precontracted guinea-pig tracheal
strips stretched at 4 and 6 g as indicated. ATP (100 nmol mlK1) was administered in control conditions or after 30 min preincubation with 100 mM ibuprofen,
1 mM diclofenac (panel A) or 100 mM L-NAME (panel B). The contraction obtained with ACh was set as 100%. Values are the meanGs.e.m. of at least four
experiments. For more details, see Section 2. Panel A: ***P!0.001 vs. all other treatments, one-way ANOVA followed by Bonferroni’s t test.
Fig. 4. Effect of thrombin (THR) on 10 nmol mlK1 ACh-precontracted
guinea-pig tracheal strips. The contraction obtained with ACh was set as
100%. Cumulative dose–response curves of THR were performed at 4 and
6 g resting tension. THR was administered as a bolus. Values are the
meanGs.e.m. of at least four experiments. For more details, see Section 3.
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NO in THR-induced relaxation using 3 U mlK1 THR. As
shown in Fig. 5 (panel A), THR-induced relaxation was not
modified by COX-inhibitors when tracheas were stretched
at 4 g. However, when resting tension was set at 6 g,
preincubation with either 10 mM ibuprofen or 1 mM
diclofenac totally prevented THR-induced relaxation
(Fig. 5(A)).
When tracheal strips were stretched at 4 g, the relaxation
induced by thrombin was significantly prevented by the
preincubation with 100 mM L-NAME (Fig. 5(B)). At the
same resting tension, the preincubation with 1 mM PTIO
also reduced the relaxing effect of thrombin (65.3G0.88%,
nZ4 vs. 55.1G5.89% control obtained in parallel exper-
iments, P!0.05 independent Student’s t test). On the
contrary, when resting tension was set at 6 g, thrombin
relaxation was not influenced by L-NAME (Fig. 5(B)) or
PTIO (not shown).
We also performed experiments using PARs activating
peptides (PARs AP). Of the peptides tested, only the PAR-
2 AP was effective in relaxing ACh-precontracted tracheas,
its effectiveness being very similar at both resting tensions.
On the contrary, PAR-1 AP, PAR-3 AP and PAR-4
AP were ineffective up to 100 nmol mlK1. The relaxant
effect of PAR-2 AP was dose-dependent in the range
1–300 nmol mlK1 (rZK0,980, P!0.05). All subsequent
experiments were performed using 100 nmol mlK1, a dose
that as shown in Table 1 was able to induce nearly 50%
relaxation at both resting tensions. The effectiveness of
PAR-2 AP was then tested in the presence of 1 mMdiclofenac and 100 mM L-NAME. L-NAME preincubation
prevented the PAR-2 AP-mediated relaxation when resting
tension was set at 4 g, whereas diclofenac was ineffective.
On the contrary, diclofenac fully prevented the relaxing
effect of PAR-2 AP at 6 g resting tension, whereas
L-NAME preincubation was totally ineffective at this
high resting tension (Table 1).
Then, experiments were done with trypsin. Also trypsin
can relax tracheas precontracted with ACh in a dose-
responsive manner in the range 10–1000 U mlK1. In order
to better characterise trypsin effectiveness, we performed
experiments using 100 U mlK1 that corresponded to
Fig. 5. Effect of COX inhibitors (panel A) and a NOS inhibitor (panel B) on THR-induced relaxation of 10 nmol mlK1 ACh-precontracted guinea-pig tracheal
strips stretched at 4 and 6 g as indicated. THR (3 U mlK1) was administered in control conditions or after 30 min preincubation with 100 mM ibuprofen or 1 mM
diclofenac (panel A) or 100 mM L-NAME (panel B). The contraction obtained with ACh was set as 100%. Values are the meanGs.e.m. of at least four
experiments. For more details, see Section 2. Panel A: ***P!0.001 vs. ibuprofen and diclofenac, one-way ANOVA followed by Bonferroni’s t test. Panel B:
***P!0.001 vs. L-NAME, one-way ANOVA.
Table 1
Relaxing effect of 100 nmol mlK1 PAR-2 AP on acetylcholine-precon-
tracted guinea-pig tracheas
Relaxation
4 g 6 g
PAR-2 AP (Control) 45.9G2.07 (8) 40.2G3.23 (8)
1 mM DiclofenacC
PAR-2 AP
43.7G1.97 (4) 2.3G0.18*§ (4)
100 mM L-NAMEC
PAR-2 AP
26.0G2.56* (4) 40.8G3.71 (4)
The contraction induced by 10 nmol mlK1 ACh was set as 100% of
contraction. Values are the meanGs.e.m. of the number of experiments in
brackets. *P!0.05 vs. the other groups at the same resting tension, one-
way ANOVA followed by Bonferroni’s t test; §P!0.05 vs. all other groups,
one-way ANOVA followed by Bonferroni’s test. At both resting tensions,
controls performed before either diclofenac or L-NAME did not differ by
more than 10% and were therefore cumulated. PAR-2 AP was administered
as a bolus on the same ACh-precontracted tracheal strips in control
conditions and after preincubation (30 min, perfusion) with either
diclofenac or L-NAME as indicated.
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100 U mlK1 trypsin are summarised in Table 2. The
relaxation induced by 100 U mlK1 trypsin was very similar
at both resting tensions and was partially prevented by 1 mM
diclofenac at both resting tensions. Also 100 mM L-NAME
partially prevented trypsin-induced relaxation at both
resting tensions.
In order to ascertain the crosstalk among the different
relaxant agents, the effectiveness of THR, trypsin and ATP
was evaluated on ACh-precontracted tracheas already
relaxed by 100 nmol mlK1PAR-2 AP. Whereas THR
3 U mlK1 induced only a small relaxation (15.8G1.65%)
of PAR-2 AP relaxed trachea (see Fig. 4 for comparison),
trypsin activity was not reduced (50.5G2.52%, nZ4, see
Table 2 for control), but was somehow strengthened.
Moreover, in tracheas already relaxed by PAR-2 AP,
100 nmol mlK1 ATP was still effective as relaxing agent
when resting tension was set at 4 g (23.3G2.09% relaxation
obtained after PAR-2 AP, nZ4 as compared to 25.5G1.39
in control condition, nZ16, see also Fig. 2). On the
contrary, the effectiveness of ATP after PAR-2 AP was
reduced at 6 g resting tension (16.5G1.66% relaxation
obtained after PAR-2 AP, nZ4 as compared to 23.5G
1.98% in control condition, nZ14, see also Fig. 2).
3.4. Effect of PGE2 and SNAP
In order to better investigate the role of PGE2 on tracheal
tone, dose–response curves of PGE2 were also made at 4 and
6 g resting tension. PGE2 (0.001–10 nmol ml
K1) adminis-
tered on non-precontracted tracheal strips induceddose-dependent (rZK0.981, P!0.001), sustained relax-
ation when resting tension was set at 6 g, the maximal
relaxation obtained using 10 nmol mlK1 PGE2 being
K11.1G2.97 mg mgK1 tissue wet weight (Fig. 6). At 4 g
resting tension, the dose-dependent (rZK0.987, P!0.001)
decrease in tone was far less pronounced: indeed the
maximal relaxation induced by 10 nmol mlK1 PGE2 was
only K2.0G0.46 mg mgK1 tissue wet weight (Fig. 6).
When a supermaximal dose of 30 nmol mlK1 PGE2 was
administered on ACh-precontracted tracheal strips, it
induced relaxation that was also resting-tension dependent,
being 91G6% at 6 g and only 30G3.5% at 4 g.
Table 2
Relaxing effect of 100 U mlK1 trypsin on acetylcholine-precontracted
guinea-pig tracheas
Relaxation
4 g 6 g
Trypsin (Control) 40.0G1.63 (8) 42.4G1.82 (8)
1 mM DiclofenacC
trypsin
28.8G1.95* (4) 18.8G2.10* (4)
100 mM L-NAMEC
trypsin
24.5G2.23* (4) 30.5G2.86* (4)
The contraction induced by 10 nmol mlK1 ACh was set as 100% of
contraction. Values are the meanGs.e.m. of the number of experiments in
brackets. *P!0.05 vs. control group at the same resting tension, one-way
ANOVA followed by Bonferroni’s t test. At both resting tensions, controls
performed before diclofenac or L-NAME did not differ by more than 10%
and were therefore cumulated. Trypsin was administered as a bolus on the
same ACh-precontracted tracheal strips in control conditions and after
preincubation (30 min, perfusion) with either diclofenac or L-NAME as
indicated.
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NO, using the NO-donor SNAP. Independently of resting
tension, SNAP induced a small relaxation on both
uncontracted and ACh-precontracted tracheas, its quantifi-
able effect being only at very high SNAP concentration.
Indeed, 100 nmol mlK1 SNAP induced a 10% relaxation in
ACh-precontracted strips. Also the effect of sodium
nitroprusside was scarce and observed only at very high
dosage.3.5. PGE2 release from tracheas
As shown in Fig. 7(A), tracheas released a quantifiable
amount of PGE2 at both resting tensions in basal conditions.
ACh administration (10 nmol mlK1) induced a small
increase in PGE2 release at both resting tensionsFig. 6. Effect of prostaglandin E2 (PGE2) on isolated guinea-pig tracheal
strips. Cumulative dose–response curves of PGE2 were performed at 4 and
6 g resting tension. PGE2 was administered as a bolus. Values are the
meanGs.e.m. of at least four experiments. Basal tension after equilibration
was assumed as 0 mg mgK1 tissue w.w. Curves were statistically analysed
using one-way ANOVA. Curves were significantly different from each
other.(not significant). Administration of ATP to ACh-precon-
tracted strips significantly increased the amount of PGE2 at
both resting tensions (P!0.05 one-way ANOVA, followed
by Bonferroni’s t test, Fig. 7(A)), the PGE2 release
measured at 6 g being significantly higher than that at 4 g
(P!0.05 one-way ANOVA, Fig. 7(A)). On the contrary,
THR was unable to increase PGE2 at both resting tensions.
In the presence of 1 mM diclofenac, PGE2 release was
strongly reduced and neither ATP nor THR administered to
ACh-precontracted strips were able to significantly increase
PGE2 release over basal values (also measured in diclofenac
preincubated strips, not shown).
3.6. NO release from tracheas
Tracheas stretched at both resting tensions released a
measurable quantity of NO in basal conditions (Fig. 7(B)).
After ACh administration, the NO release from tracheas was
not modified. The administration of either ATP or THR did
not change the NO production at both resting tension, but a
small, not significant increase in NO release was measured
when THR was administered to ACh-precontracted tracheal
strips at 4 g but not at 6 g. In the presence of 100 mM
L-NAME, the increased quantity of THR was reduced in all
conditions (data not shown).4. Discussion
According to our data, in isolated guinea-pig tracheas the
relaxation induced by PAR agonists is dependent on
epithelial-produced autacoids (i.e. NO and PGE2), but
their relative potency as relaxant agonists is dependent on
resting tension and therefore on smooth muscle length. This
resting tension dependency is a peculiar characteristic of
PAR-induced relaxation, while ATP effect is not influenced
by it. We would like to point out that the resting tensions
used for our investigation were selected to produce a similar
contractile effect in the full ACh dose–response range.
Moreover, precontracted tracheas with the maximal effec-
tive ACh dose can still strongly react to high potassium.
Interestingly, according to our preliminary data, at low
resting tension (2 g) ACh contraction reaches higher values
in the upper part of the dose response curve (4.9G0.25 and
5.1G0.21 at 100 and 300 nmol mlK1 ACh, respectively),
but both ATP and THR are ineffective in inducing a
quantifiable relaxation.
According to the literature, ATP can moderately relax
ACh-precontracted preparations in a dose-dependent way
[11]. The ATP-induced relaxation is prevented when COX-
inhibitors are used. These data strongly indicate that ATP
relaxation is fully dependent on the relaxing COX
metabolite PGE2. Since ATP is ineffective in epithelial
rubbed preparations, PGE2 are probably released from the
epithelial layer. These data are in line with previous reports
in which ATP can relax guinea-pig tracheal preparations
Fig. 7. Release of PGE2 and NO from isolated guinea-pig tracheal strips. Panel A: PGE2 was measured by RIA (performed in duplicate) on the supernatant
obtained from isolated guinea-pig tracheal strips preloaded either at 4 or 6 g resting tension and under basal conditions, after administration of 10 nmol mlK1
ACh alone (6 min) or after administration of 10 nmol mlK1 ACh (3 min) plus 100 nmol mlK1 ATP (3 min) or 10 nmol mlK1 ACh (3 min) plus 3 U mlK1 THR
(3 min) as indicated. Basal value indicates the PGE2 amount in the supernatant collected from the closed organ bath (6 min) after tissue equilibration in each
experimental condition. For more details, see Section 2. Values are the meanGs.e.m. of eight experiments. *P!0.05 vs. basal conditions and § vs. ATP 6 g
resting tension, repeated measured ANOVA, followed by Bonferroni’s t test. Panel B: NO was measured by a chemilluminescent method on the supernatant
obtained from isolated guinea-pig tracheal strips preloaded either at 4 or 6 g resting tension and under basal conditions, after administration of 10 mmol mlK1
ACh alone (6 min) or after administration of 10 mmol mlK1 ACh (3 min) plus mmol mlK1 ATP (3 min) or 10 mmol mlK1 ACh (3 min) plus 3 U mlK1 THR
(3 min) as indicated. Basal value indicates the NO amount in the supernatant collected from the closed organ bath (6 min) after tissue equilibration in each
experimental condition. For more details, see Section 2. Values are the meanGs.e.m. of six experiments.
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dependent manner. Moreover, in agreement with the
functional experiments the direct quantification of PGE2
production demonstrates that ATP is able to increase PGE2
release at both resting tensions tested. To note that at 6 g,
ATP-induced PGE2 release is higher than at 4 g resting
tension, but this high production does not increase
relaxation. This is also interesting since according to our
data exogenous administered PGE2 is more effective at high
resting tension.
On the other hand, inhibition of NO production by the
NOS inhibitor L-NAME or NO trapping by PTIO do not
modify the trachea’s sensitivity to ATP relaxation. More-
over, ATP does not modify NO release as determined by the
direct dosage. Although the direct dosage NO can suffer
from several intrinsic problems, altogether these data
indicate that NO release is not involved in ATP-induced
relaxation. Therefore, we can conclude that ATP-induced
relaxation is fully dependent on PGE2 pathway indepen-
dently of resting tension.
More intriguing is the relaxant effect of THR, trypsin and
PARs agonist peptides. Thrombin is a multifunctional
protease that plays important roles in thrombotic, inflam-
matory, proliferative, and atherosclerotic processes.
The significance of the coagulation factors in the
airways is still only partially understood. However, the
finding that an increased THR concentration has been
measured in the sputum of patients with bronchial asthma[14], in the bronchoalveolar lavage (BAL) of patients with
pulmonary fibrosis [15] and allergic asthma after segmental
bronchoprovocation (SBP) with antigen [16], suggests that
THR may play a role in several inflammatory lung diseases.
According to our data, THR relaxes ACh-precontracted
tracheas, its dose–response curves being very similar at both
resting tensions. However, at 4 g the THR relaxing effect is
not inhibited by COX-inhibitors, whereas the NOS inhibitor
L-NAME prevents this relaxation. The involvement of NO
in this relaxation is further confirmed by the efficacy of the
NO trapping agent PTIO. Conversely, NOS inhibition is
ineffective at 6 g, whereas the COX inhibitors totally
prevent THR-induced relaxation. These data imply that
THR-induced relaxation is dependent on NO pathway at
low resting tension relaxation, whereas at higher resting
tension, the COX pathway is mainly involved.
Our quantitative results only partially substantiate
functional data obtained using THR. Indeed, according to
the quantitative dosages, THR determines only a small, not
significant increase in NO release at 4 g resting tension and
is also unable to significantly increase PGE2 release at 6 g.
Although we cannot completely exclude a role of other
COX-dependent metabolites in the relaxation induced by
THR at 6 g, relaxing lipid autacoids such as prostaglandin I2
are less produced than PGE2 in guinea-pig trachea [17].
However, the direct dosage of autacoid release in the
perfusion buffer can only partially reflect the real autacoid
production and their concentration in the cellular and
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trapped by several tissue components such as lipids and
proteins. In particular NO can rapidly react to thiol groups,
producing S-nitroso compounds and/or to O2 bubbled in the
organ bath as an oxycarb mixture. The high NO reactivity to
cellular components and the experimental apparatus could
also explain the high variability of the NO dosage.
Our data also show that the relaxant effect of exogenous
PGE2 is strongly influenced by resting tension, their
effectiveness as relaxing agent in ACh-precontracted
preparations being more than 90% when resting tension is
set at 6 g, but only 30% when it is 4 g. Therefore, the
relevance of the COX pathway in the relaxation induced by
THR at 6 g can depend on the great effectiveness of PGE2 at
this high resting tension more than a direct increase in its
production.
The high relaxant response to exogenously administered
PGE2 at high resting tension is quite intriguing. In the
guinea-pig trachea, PGE2 administration, by stimulating its
EP2 receptor, can increase adenosine 3 0:5 0 cyclic mono-
phosphate (cAMP, [18]), that phosphorylates several
substrates through the activation of protein kinase A
(cAK). Among target proteins for cAK, a prominent role
is played by calcium-activated potassium channel, the high
conductance Ca2C-activated KC (BKCa) channels [19].
Potassium channels can be influenced in a complex way by
stretch in smooth muscle cells [20,21] and phosphorylation
via different kinases [22,23]. Also, the blockade of BKCa in
guinea-pig trachea can reduce cAMP-dependent relaxation
of isolated trachea [24], so it seems likely that the stretch-
dependent effect of agonists may be influenced by these
mechanisms. Therefore, the different effectiveness of PGE2
according to resting tension may be mediated by the
different status of BKCa. Therefore, according to resting
tension, BKCa status can also influence the THR-mediated
relaxation. Further functional experiments using specific
potassium channel blockers might explore this topic.
NO-releasing drugs such SNAP and sodium nitroprus-
side have low effectiveness and their action is not influenced
by resting tension. However, NO-releasing molecules
cannot fully mimic endogenous NO, since kinetic release
and cellular localization can differ remarkably.
In our experiments, only the PAR-2 AP relaxes the ACh-
precontracted trachea and its action reproduces more the
relaxing effect of THR than that of trypsin in regard to the
sensitivity of NOS and COX inhibitors, NOS and COX
inhibitors preventing the tissue relaxation induced by PAR-
2 AP at 4 and 6 g, respectively. Also the results obtained
using ATP in tracheas already relaxed by PAR-2 AP are in
line with a predominant role of NOS at 4 g and COX at 6 g.
Indeed, ATP relaxation (totally dependent on COX at both
resting tensions) is unmodified at 4 g, but strongly reduced
at 6 g when measured in presence of COX inhibitors.
According to the current literature, THR is a powerful
agonist of PAR-1, a weak agonist of PAR-3 and PAR-4,
whereas it seems to be ineffective on PAR-2, that can beactivated by trypsin and tryptase [25]. However, according
to our data, only PAR-2 AP can induce reliable relaxation,
whereas the other three peptides are ineffective at
concentrations up to 100 nmol mlK1. Moreover, our data
demonstrate that THR is no far effective as relaxant agent in
tracheas already relaxed by PAR-2 AP, thus suggesting a
partial or total cross-reactivity on the same receptor subtype.
Since PARs antagonists are not well described, we cannot
fully address this question. Nevertheless, other authors find
a partial cross-reactivity between THR and PAR2 AP [9,26,
27]. The PARs-activating peptides used in our experiments
can increase intracellular calcium concentration in coronary
endothelial cells isolated from the guinea-pig heart accord-
ing to our standard protocol [28], thus ruling out the
possibility that these peptides may be biologically ineffec-
tive on guinea-pigs, their potency being as follows: PAR-1
AP\PAR-2 AP[PAR-3 APZPAR-4 AP.
Trypsin can also relax ACh-precontracted strips, its
relaxant effect at 100 U mlK1 being partially inhibited by
diclofenac and L-NAME at 4 and 6 g resting tension.
Diclofenac prevents trypsin-induced relaxation more effec-
tively at 6 g, whereas L-NAME is more effective at 4 g.
Therefore, the relaxing effect of 100 U mlK1 trypsin is
dependent on NO production and COX metabolites at both
resting tensions. The relaxing effect of trypsin differs from
that of THR and PAR-2 AP, suggesting a more complex
relationship among receptor subtype activation and intra-
cellular mediators. The finding that trypsin is still fully
effective as relaxant agent in tracheas already relaxed by
PAR-2 AP, corroborates the hypothesis that trypsin and
PAR-2 AP, at least in our experimental conditions, can
activate different receptor subtypes. These results suggest
that in our model THR can directly activate PAR-2, while
trypsin relaxation seems to be partially or totally dependent
on other relaxing mechanisms.
In conclusion, our data can explain several discrepancies
as regards the responsiveness to PARs agonists in different
preparations, where a crucial role is played by resting
tension. These results also suggest that endogenous
autacoids as well as therapeutic drugs may produce different
effects, depending on stretch. These considerations should
be taken into account, not only in terms of isolated
experiments in vitro, but also in vivo, since cell length in
bronchial trees is submitted to natural cyclic changes during
breathing. A stretch-dependent dual regulation of the
relaxant efficacy of endogenous autacoids (i.e. NO and
PGE2) according to smooth muscle length could be a
naturally occurring mechanism preventing desensitization
of important smooth muscle tone regulators.
Our data can also explain several discrepancies in the
literature, since many experimental settings can influence
tissue tension and cell length. Indeed, the resting tension and
use of contractile agonists can vary the strength that is
imposed to tissue preparations.
Moreover, our results may also contribute to clarify the
role of proteases in lung pathophysiology. Although all
S. Franchi-Micheli et al. / Pulmonary Pharmacology & Therapeutics 18 (2005) 141–150150THR concentrations used in our experiments are lower [16]
or higher [15] than those founded in BAL patients with
different inflammatory lung diseases, at least in the presence
of an intact epithelium, thrombin is able to relax tracheal
smooth muscle, thus suggesting a protective role for this
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